A carregar...
CTIM-17. PHASE I STUDY OF THE SAFETY AND IMMUNOGENICITY OF PERSONALIZED NEOANTIGEN VACCINES AND TUMOR TREATING FIELDS IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
BACKGROUND: Glioblastoma (GBM) generates mutation-derived tumor antigens, which arise from somatic variants that result in mutated protein fragments displayed to immune cells. These mutated proteins can provide targets for anti-tumor personalized neoantigen vaccine (PNV) therapy. Combining PNV with...
Na minha lista:
| Publicado no: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7650510/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.151 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|